Journals / Solunum / 2016 / Cilt: 18 - Sayı: 2

Therapeutic options for bronchiolitis obliterans syndrome after lung transplantation

Journal
Solunum
Pages
63–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the context of an illustrative case report, we review hereby the current literature regarding these different treatment options

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following lung transplantation and limits patients' long-term outcome.
📊
Key Findings & Data:Within the group of emerging CLAD phenotypes, bronchiolitis obliterans syndrome is the most common form and observed in up to 75% of lung transplant recipients 10 years after transplantation.
💡
Conclusion & Impact:In the context of an illustrative case report, we review hereby the current literature regarding these different treatment options
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following lung transplantation and limits patients' long-term outcome. Within the group of emerging CLAD phenotypes, bronchiolitis obliterans syndrome is the most common form and observed in up to 75% of lung transplant recipients 10 years after transplantation. Therapeutic options to address BOS are limited and, at our center, include modification of immunosuppression, immunomodulation using macrolide antibiotics, the use of statins, leukotriene receptor antagonists, and extracorporeal photopheresis. The evidence for most of these therapy options is derived from case reports or small, descriptive studies, whereas controlled trials are yet to be conducted. In the context of an illustrative case report, we review hereby the current literature regarding these different treatment options

🔖

Cite This Article

HANGARTNER, N., SCHUURMANS, M. M., MURER, C., BENDEN, C., HUBER, L. C. (2016). Therapeutic options for bronchiolitis obliterans syndrome after lung transplantation. Solunum, Cilt: 18 - Sayı: 2, 63–69. https://ajindex.com/articles/314251

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classifica- tion system for chronic lung allograft dysfunction. J Heart Lung Trans- plant 2014
  2. [CrossRef] Suwara MI, Vanaudenaerde BM, Verleden SE, Vos R, Green NJ, Ward C, et al. Mechanistic differences between phenotypes of chronic lung al- lograft dysfunction after lung transplantation. Transpl Int 2014
  3. [CrossRef] Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dip- chand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013
  4. focus theme: age. J Heart Lung Transplant 2013
  5. [CrossRef] 4. Penninga L, Penninga EI, Møller CH, Iversen M, Steinbrüchel DA, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung trans-plant recipients. Cochrane Database Syst Rev 2013
  6. CD008817. [CrossRef ] 5. Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995
  7. [CrossRef ] 6. Zuckermann A, Reichenspurner H, Birsan T, Treede H, Deviatko E, Reich-art B, et al. Cyclosporine A versus tacrolimus in combination with my-cophenolate mofetil and steroids as primary immunosuppression after lung transplantation: One-year results of a 2-center prospective random-ized trial. J Thorac Cardiovasc Surg 2003
  8. [CrossRef ] 7. Hachem RR, Yusen RD, Chakinala MM, Meyers BF, Lynch JP, Aloush AA, et al. A Randomized Controlled Trial of Tacrolimus Versus Cyclosporine Af-ter Lung Transplantation. The Journal of Heart and Lung Transplantation 2007
  9. [CrossRef ] 8. Treede H, Glanville AR, Klepetko W, Aboyoun C, Vettorazzi E, Lama R, et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospec-tive, randomized international trial in lung transplantation. J Heart Lung Transplant 2012
  10. [CrossRef ] 9. Stuckey LJ, Walker NM, Lin J, Chan KM, Lama VN. Halting BOS in Lung Transplant: Is Cyclosporine Conversion the Answer? J Heart Lung Trans-plant 2014
  11. S294. [CrossRef ] 10. Ross DJ, Lewis MI, Kramer M, Vo A, Kass RM. FK 506 "rescue" immunosup-pression for obliterative bronchiolitis after lung transplantation. Chest 1997
  12. [CrossRef ] 11. Revell MP, Lewis ME, Llewellyn-Jones CG, Wilson IC, Bonser RS. Conserva-tion of small-airway